This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dusman, R. E. Articles by Heger, J. J. Search for Related Content PubMed PubMed Citation Articles by Dusman, R. E. Articles by Heger, J. J.

Circulation, Vol 82, 51-59, Copyright © 1990 by American Heart Association

ARTICLES

Clinical features of amiodarone-induced pulmonary toxicity

RE Dusman, MS Stanton, WM Miles, LS Klein, DP Zipes, NS Fineberg and JJ Heger
Krannert Institute of Cardiology, Department of Medicine, Indiana University School of Medicine, Indianapolis 46202.

The incidence and clinical predictors of amiodarone pulmonary toxicity were examined in 573 patients treated with amiodarone for recurrent ventricular (456 patients) or supraventricular (117 patients) tachyarrhythmias. Amiodarone pulmonary toxicity was diagnosed in 33 of the 573 patients (5.8%), based on symptoms and new chest radiographic abnormalities (32 of 33 patients) and supported by abnormal pulmonary biopsy (13 of 14 patients), low pulmonary diffusion capacity (DLCO) (nine of 13 patients), and/or abnormal gallium lung scan (11 of 16 patients). Toxicity occurred between 6 days and 60 months of treatment for a cumulative risk of 9.1%, with the highest incidence occurring during the first 12 months (18 of 33 patients). Older patients developed it more frequently (62.7 +/- 1.7 versus 57.4 +/- 0.5 years, p = 0.018), with no cases diagnosed in patients who started therapy at less than 40 years of age. Gender, underlying heart disease, arrhythmia, and pretreatment chest radiographic, spirometric, or lung volume abnormalities did not predict development of amiodarone pulmonary toxicity, whereas pretreatment DLCO was lower in the group developing it (76.0 +/- 5.5% versus 90.4 +/- 1.4%, p = 0.01). There was a higher mean daily amiodarone maintenance dose in the pulmonary toxicity group (517 +/- 25 versus 409 +/- 6 mg, p less than 0.001) but no difference in loading dose. No patient receiving a mean daily maintenance dose less than 305 mg developed pulmonary toxicity. Patients who developed toxicity had higher plasma desethylamiodarone (2.34 +/- 0.18 versus 1.92 +/- 0.04 micrograms/ml, p = 0.009) but not amiodarone concentrations during maintenance therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				B. J. Barnes, E. A. Kirkland, P. A. Howard, D. W. Grauer, M. E. Gorton, J. B. Kramer, G. F. Muehlebach, and W. A. Reed Risk-stratified evaluation of amiodarone to prevent atrial fibrillation after cardiac surgery. Ann. Thorac. Surg., October 1, 2006; 82(4): 1332 - 1337. [Abstract] [Full Text] [PDF]

				F. Bokhari, D. Newman, M. Greene, V. Korley, I. Mangat, and P. Dorian Long-Term Comparison of the Implantable Cardioverter Defibrillator Versus Amiodarone: Eleven-Year Follow-Up of a Subset of Patients in the Canadian Implantable Defibrillator Study (CIDS) Circulation, July 13, 2004; 110(2): 112 - 116. [Abstract] [Full Text] [PDF]

				C.-H. Tsou, C.-E. Chiang, J.-T. Liou, S.-T. Hsin, and H.-N. Luk Successful use of iv diltiazem to control perioperative refractory complex atrial tachyarrhythmias in a patient with pneumoconiosis: [L'utilisation reussie du diltiazem iv dans le controle de tachyarythmies perioperatoires, auriculaires, refractaires, complexes, chez un malade souffrant de pneumoconiose] Can J Anesth, January 1, 2003; 50(1): 36 - 41. [Abstract] [Full Text] [PDF]

				S. Kaushik, A. Hussain, P. Clarke, and H. L. Lazar Acute pulmonary toxicity after low-dose amiodarone therapy Ann. Thorac. Surg., November 1, 2001; 72(5): 1760 - 1761. [Abstract] [Full Text] [PDF]

				H. Ashrafian and P. Davey Is Amiodarone an Underrecognized Cause of Acute Respiratory Failure in the ICU? Chest, July 1, 2001; 120(1): 275 - 282. [Abstract] [Full Text] [PDF]

				D. J. Goldstein, M. C. Oz, and E. A. Rose Implantable Left Ventricular Assist Devices N. Engl. J. Med., November 19, 1998; 339(21): 1522 - 1533. [Full Text] [PDF]

				M. H. Eckman, R. H. Falk, and S. G. Pauker Cost-effectiveness of Therapies for Patients With Nonvalvular Atrial Fibrillation Arch Intern Med, August 10, 1998; 158(15): 1669 - 1677. [Abstract] [Full Text]

				The Antiarrhythmics versus Implantable Defibrillat A Comparison of Antiarrhythmic-Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-Fatal Ventricular Arrhythmias N. Engl. J. Med., November 27, 1997; 337(22): 1576 - 1584. [Abstract] [Full Text] [PDF]